Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer Guimbellot

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Pediatric Pulmonology|September 8, 2017
Toward inclusive therapy with CFTR modulators: Progress and challengesJennifer Guimbellot, Jyoti Sharma, Steven M Rowe
Experimental Cell Research|October 22, 2003
EWS/FLI function varies in different cellular backgroundsJeffrey P Zwerner, Jennifer Guimbellot, William A May
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|April 25, 2018
Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutationsJennifer Guimbellot, George M Solomon, Arthur Baines, et al.
Pediatric Pulmonology|June 24, 2020
Highlights from the 2019 North American Cystic Fibrosis ConferenceJordana E Hoppe, Jennifer Guimbellot, Stacey L Martiniano, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|October 5, 2023
Patient perspectives on elexacaftor/tezacaftor/ivacaftor after lung transplantDave Young, Lauren E Bartlett, Jennifer Guimbellot, et al.
Plos One|November 29, 2023
Prime editing-mediated correction of the CFTR W1282X mutation in iPSCs and derived airway epithelial cellsChao Li, Zhong Liu, Justin Anderson, et al.
American Journal of Respiratory and Critical Care Medicine|September 24, 2024
Ivacaftor for Chronic Obstructive Pulmonary Disease - Results from a Phase 2, Randomized Controlled TrialKadambari Vijaykumar, George M Solomon, Jennifer Guimbellot, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Pediatric Pulmonology|September 8, 2017
Toward inclusive therapy with CFTR modulators: Progress and challengesJennifer Guimbellot, Jyoti Sharma, Steven M Rowe
Experimental Cell Research|October 22, 2003
EWS/FLI function varies in different cellular backgroundsJeffrey P Zwerner, Jennifer Guimbellot, William A May
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|April 25, 2018
Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutationsJennifer Guimbellot, George M Solomon, Arthur Baines, et al.
Pediatric Pulmonology|June 24, 2020
Highlights from the 2019 North American Cystic Fibrosis ConferenceJordana E Hoppe, Jennifer Guimbellot, Stacey L Martiniano, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|October 5, 2023
Patient perspectives on elexacaftor/tezacaftor/ivacaftor after lung transplantDave Young, Lauren E Bartlett, Jennifer Guimbellot, et al.
Plos One|November 29, 2023
Prime editing-mediated correction of the CFTR W1282X mutation in iPSCs and derived airway epithelial cellsChao Li, Zhong Liu, Justin Anderson, et al.
American Journal of Respiratory and Critical Care Medicine|September 24, 2024
Ivacaftor for Chronic Obstructive Pulmonary Disease - Results from a Phase 2, Randomized Controlled TrialKadambari Vijaykumar, George M Solomon, Jennifer Guimbellot, et al.
Pageof 1